**Core tip:** This study evaluates the prognostic significance of clinico-pathological variables in patients with locally advanced rectal carcinoma treated with neo-adjuvant chemo-radiotherapy (CRT) and surgery. Our data show that tumors with cN+ status, extensive/lower involvement of the rectum, mucinous histotype and poor differentiation have a lower response to pre-operative CRT. Dworak tumor regression grade was prognostically informative; however, a simplified two-tiered system was more reproducible and prognostically significant. Acellular mucin pools were found in a percentage of cases with excellent outcomes. Although acellular mucin pools should be considered as complete pathological responses, careful histological examination is mandatory to exclude residual mucinous carcinoma.

INTRODUCTION
============

Neo-adjuvant chemo-radiotherapy (CRT) currently represents the standard of care for locally advanced (clinical T stage 3/4 or N+) rectal cancer\[[@B1],[@B2]\]. Indeed, CRT improves resectability and sphincter preservation and decreases the probability of local recurrence in patients affected by rectal carcinoma\[[@B3],[@B4]\]. However, tumor response to CRT is highly heterogeneous and governed by unclear mechanisms\[[@B5]\]. Post-treatment Tumor Node Metastasis (yTNM) stage and Tumor Regression Grade (TRG) are currently used to measure tumor response in surgical specimens obtained after CRT. According to several studies, TRG seems to have prognostic relevance on both disease-free survival (DFS) and overall survival in patients with rectal cancer\[[@B6]-[@B9]\]. Several systems have been proposed to score TRG, and all are based on the proportion of residual tumor to stromal fibrosis in the primary tumor site\[[@B10]-[@B13]\]. However, none of the systems currently in use is universally accepted, and all may have fair interobserver concordance due to the lack of precise and objective criteria for scoring\[[@B14]\]. Of note, several authors reported on the presence of mucin pools devoid of neoplastic cells in surgical rectal carcinomas pre-treated with CRT with an incidence ranging between 4.8% and 31%\[[@B15]-[@B19]\]. One issue in the assessment of TRG of rectal cancer relates to the interpretation of acellular mucin pools\[[@B15]-[@B19]\]. Indeed, only the TRG proposed by the Royal College of Pathologists clearly states that acellular mucin pools should be regarded as complete tumor regression\[[@B20]\], while the other grading systems do not give a precise indication on this topic. Additionally, only a few papers addressed the prognostic significance of acellular mucin pools in rectal cancer treated with neo-adjuvant therapy and these studies reported controversial findings\[[@B15]-[@B19]\]. Further, some authors suggest that acellular mucin deposits are associated with higher biological aggressiveness of the tumor\[[@B16]\], while others do not find any association with patient prognosis\[[@B15],[@B17]-[@B19]\]. Finally, whether development of acellular mucin pools is associated with any of the clinico-pathological characteristics present in the tumor prior to CRT is still to be determined.

In this study, we analyzed a cohort of rectal carcinomas submitted to neo-adjuvant CRT with the aim to investigate: (1) the reproducibility and prognostic significance of Dworak TRG\[[@B11]\]; (2) the prognostic significance of acellular mucin pools; and (3) the possible correlation between TRG, acellular mucin pools or TNM stage variation after therapy and the various clinico-pathological characteristics present in the tumor before treatment.

MATERIALS AND METHODS
=====================

A total of 238 rectal adenocarcinomas, treated by neoadjuvant CRT and surgical resection with mesorectal excision, were identified in the Tumor Registry of Colorectal Cancer of the University of Modena and Reggio Emilia, Italy, in the period between 2001 and 2012.

Twenty-three patients were excluded from this study because they had clinical TNM (cTNM) stage IV. Thus, the final cohort in this analysis was composed of 215 patients (141 males, 74 females; mean age: 66.3 years; age range: 30-85 years) with cT3/T4 or cN+ rectal cancer. cTNM staging workup had been performed by using digital rectal examination, chest radiography, total-body computed tomography (CT), magnetic resonance imaging, endorectal ultrasonography and coloscopy with biopsy.

Clinical records were reviewed to retrieve information on the localization in the rectum (upper, medium, lower or extensive), the circumferential involvement of the rectal wall (one-third, middle or complete), distance from the anal verge (more or less than 1 cm) and craniocaudal extension (more or less than 3 cm) of the tumor. The histological grade and histotype of the tumor were assessed using endoscopic biopsy and according to World Health Organization criteria\[[@B21],[@B22]\].

After the histological diagnosis on endoscopic biopsy, all patients received a total dose of 50 Gy radiotherapy, which was administered in 28 fractions of 1.8 Gy each for five consecutive days per week, and a daily continuous infusion of 225 mg 5-fluorouracil per day and per square meter of body surface for the duration of radiotherapy.

Then, patients were submitted to surgical resection. Data on cancer-specific survival (CSS) and DFS were available for all patients. After surgery, patients were monitored for disease progression by using total-body CT scan, coloscopy and blood tests (including measurement of CEA and CA 19-9). Patients who died of diseases independent of rectal cancer were censored. Both local and distant recurrences were considered in the assessment of DFS. Information on eventual adjuvant therapy was available for 127 patients.

Pathological examination
------------------------

Surgical specimens were fixed in formalin for 24 h at room temperature and were grossly examined for obvious or presumable tumor remains as a mass, ulcer or fibrotic lesion. At least 3 samples were taken for paraffin embedding from specimens showing an obvious tumor mass. On the other hand, lesions with questionable residual tumors were completely embedded, and if no tumor cells were detected on first paraffin sections, three additional leveled sections were examined from each paraffin block. The total number of paraffin blocks from the primary tumor region ranged between 3 and 25; the average number was 6.4. In each case, at least 12 lymph nodes were retrieved from perirectal fat.

The histological slides of each case were retrieved from the archive of the Unit of Anatomic Pathology of the University of Modena and Reggio Emilia and reviewed by two independent pathologists (L.R.B. and V.B.) to assess the TRG and yTNM staging.

TRG was assessed in the primary tumor, but not in nodal metastases, according to Dworak scale\[[@B11]\]. In detail, cases were defined as follows: grade 0, no regression; grade 1, dominant tumor mass with obvious fibrosis and⁄or vasculopathy; grade 2, dominant fibrotic changes with few neoplastic cells or groups (easy to find); grade 3, evidence of very few neoplastic cells in fibrotic tissue; and grade 4, no tumor cells (pathological complete response)\[[@B11]\]. Cases showing acellular mucin pools were initially considered separately and then categorized as grade 4 because of the absence of tumor cells.

yTNM staging was established using the criteria of Union for International Cancer Control (UICC) (TNM 7^th^ edition)\[[@B23]\].

We also evaluated the status of the radial (circumferential resection) margin, which was defined as positive when normal tissue from the edge of the tumor measured 1 mm or less\[[@B24]\].

In the comparison between cTNM and yTNM, we were able to establish the variation rate of T, N and TNM staging after neoadjuvant CRT and define three groups of tumors, as follows: (1) rectal cancer with no change in TNM staging; (2) rectal cancers with downstaging after therapy; and (3) rectal carcinomas with upstaging after therapy.

Statistical analysis
--------------------

Fleiss-Cohen weighted κ statistics were used to establish interobserver variability in the assessment of TRG.

The *χ*^2^ test was applied to analyze the statistical correlations between Dworak TRG and the various clinico-pathological parameters and to investigate the statistical association between acellular mucin pools and clinico-pathological variables in the subgroup of Dworak grade 4 tumors.

We also used the *χ*^2^ test to establish the statistical correlation between T, N, or TNM stage changing and the other clinico-pathological parameters.

DFS and CSS were assessed by the Kaplan-Meier method, using the date of primary surgery as the entry date. The end point for the DFS analysis was the length of survival to disease progression (either local or distant). CSS was characterized as the length of survival to death from rectal cancer or to the last follow-up date. For DFS and CSS analyses, Dworak grades 0, 1 and 2 were grouped and defined as absent/partial regression, while grades 3 and 4 were grouped together and considered as total/subtotal regression.

The Mantel-Cox log-rank test was applied to assess the strength of the association between DFS or CSS and each of the parameters (age and gender of the patient as well as site, circumferential spread, distance from the anal verge, craniocaudal extension, histological grade, histotype, cT, cN, yT, yN, yM, yTNM stage, T stage variation, N stage variation, TNM stage variation, radial margin, Dworak regression grade, tumor regression, and adjuvant chemotherapy) as a single variable.

Subsequently, a stepwise multivariate analysis (Cox regression model) was utilized to determine the independent effect of each variable on survival. TNM stage variation (and not single T or N stage variation) and tumor regression (not Dworak regression grade) were included in the multivariate analyses. Adjuvant chemotherapy was not considered in the multivariate analyses because data were available in only a proportion of patients.

A probability (*P*) value less than 0.05 was considered significant. Statistical analysis was performed using MedCalc 12.1.4.0 statistical software (MedCalc Software, Mariakerke, Belgium).

RESULTS
=======

The clinico-pathological characteristics of rectal cancer in the study are summarized in Table [1](#T1){ref-type="table"}. The median follow-up period of the patients was 70 mo (range: 3-183 mo). During the follow-up 73 (34%) patients developed recurrences, and 58 died of disease.

###### 

Clinico-pathological features of 215 rectal carcinomas treated with neo-adjuvant chemo-radiotherapy *n* (%)

  **Variables**                  **Category**     ***n***   **Death due to disease**   **Recurrence**
  ------------------------------ ---------------- --------- -------------------------- ----------------
  Sex                            M                141       35 (25)                    43 (30)
  F                              74               23 (31)   30 (40)                    
  Age                            ≤ 67 yr          106       24 (23)                    32 (30)
  \> 67 yr                       109              34 (31)   41 (38)                    
  Site                           Upper            93        23 (25)                    30 (32)
  Medium                         32               10 (31)   13 (41)                    
  Lower                          77               21 (27)   26 (34)                    
  Extensive                      13               4 (31)    4 (31)                     
  Circumferential spread         One-third        94        24 (26)                    32 (34)
  One middle                     62               17 (27)   21 (34)                    
  Complete                       59               17 (29)   20 (34)                    
  Craniocaudal extension         \< 3 cm          51        7 (14)                     10 (20)
  ≥ 3 cm                         164              51 (31)   63 (38)                    
  Distance from the anal verge   ≥ 1 cm           204       56 (27)                    2 (18)
  \< 1 cm                        11               2 (18)    71 (35)                    
  Histological grade             1                6         0 (0)                      0 (0)
  2                              179              47 (26)   61 (34)                    
  3                              30               11 (37)   12 (40)                    
  Histotype                      NOS              200       53 (26)                    67 (33)
  Mucinous                       15               5 (33)    6 (40)                     
  cT                             cT2              12        1 (8)                      2 (17)
  cT3                            170              43 (25)   54 (32)                    
  cT4                            33               14 (42)   17 (51)                    
  cN                             cN0              98        21 (21)                    28 (28)
  cN+                            117              37 (32)   45 (38)                    
  yT                             yT0              35        3 (9)                      8 (23)
  yT1                            19               1 (5)     1 (5)                      
  yT2                            61               13 (21)   16 (26)                    
  yT3                            83               32 (39)   36 (43)                    
  yT4                            17               9 (53)    12 (70)                    
  yN                             yN0              146       28 (91)                    38 (26)
  yN+                            69               30 (43)   35 (51)                    
  yM                             yM0              212       56 (20)                    70 (33)
  yM+                            3                2 (67)    3 (100)                    
  y stage                        T0N0M0           33        3 (9)                      8 (24)
  1                              63               10 (16)   13 (21)                    
  2                              50               15 (30)   17 (34)                    
  3                              66               28 (42)   32 (48)                    
  4                              3                2 (67)    3 (100)                    
  TNM Stage variation            None             80        33 (41)                    38 (47)
  Downstaging                    119              19 (16)   28 (23)                    
  Upstaging                      16               6 (38)    7 (44)                     
  T stage variation              None             86        34 (40)                    41 (48)
  Downstaging                    122              22 (18)   29 (24)                    
  Upstaging                      7                2 (29)    3 (43)                     
  N stage variation              None             141       43 (31)                    55 (39)
  Downstaging                    61               11 (18)   14 (23)                    
  Upstaging                      13               4 (31)    4 (31)                     
  Dworak Regression grade        0                34        16 (47)                    19 (56)
  1                              76               20 (26)   26 (24)                    
  2                              50               16 (32)   16 (32)                    
  3                              21               3 (14)    4 (19)                     
  4                              34               3 (9)     8 (23)                     
  Regression                     Absent/partial   160       52 (33)                    61 (38)
  Total/subtotal                 55               6 (11)    12 (22)                    
  Radial margin                  Negative         201       51 (25)                    65 (32)
  Positive                       14               7 (50)    8 (57)                     
  Adjuvant chemotherapy          No               47        16 (34)                    18 (38)
  Yes                            80               24 (30)   31 (39)                    

The Dworak grade could be assessed in all 215 cases. Interobserver concordance in the assessment of Dworak TRG was good (K: 0,74) and increased to very good (K: 0.82) when cases were subdivided into total/subtotal regression (Dworak grades 3 and 4) and absent/partial regression (Dworak grades 0, 1 and 2).

In detail, 34 (16%) rectal carcinomas were classified as Dworak grade 0, 76 (35%) as grade 1, 50 (23%) as grade 2 (Figure [1A](#F1){ref-type="fig"}), 21 (10%) as grade 3 and 34 (16%) as grade 4 (Figure [1B](#F1){ref-type="fig"} and Table [1](#T1){ref-type="table"}). Lower Dworak grade (0/1/2) was significantly more frequent among cN+ tumors (cTNM stage III) (*P* = 0.0008) (Figure [2](#F2){ref-type="fig"}) and was also significantly associated with death from rectal cancer (*P* = 0.0047) and recurrence (*P* = 0.0254) (Table [2](#T2){ref-type="table"}).

![Tumor regression in rectal surgical specimens after neo-adjuvant chemo-radiotherapy. A: Dworak grade 2, corresponding to dominant fibrosis with few neoplastic cells or groups; B: Dworak grade 4, showing no tumor cells (pathological complete response); C: Acellular mucin pools.](WJG-23-1412-g001){#F1}

###### 

Statistical correlations between Dworak regression grade and clinico-pathological variables

  **Variable**                   **Dworak regression grade**   ***P* value**                  
  ------------------------------ ----------------------------- --------------- ---- ---- ---- --------
  Sex                                                                                         
  M                              23                            52              29   11   26   0.285
  F                              11                            24              21   10   8    
  Age                                                                                         
  ≤ 67 yr                        14                            35              32   9    16   
  \> 67 yr                       20                            41              18   12   18   0.202
  Site                                                                                        
  Upper                          9                             37              22   8    17   
  Medium                         7                             11              7    1    6    
  Lower                          13                            23              19   11   11   
  Extensive                      5                             5               2    1    0    0.2506
  Circumferential spread                                                                      
  One-third                      14                            30              28   8    14   
  Middle                         12                            19              10   9    12   
  Complete                       8                             27              12   4    8    0.31
  Craniocaudal extension                                                                      
  \< 3 cm                        8                             15              13   6    9    
  ≥ 3 cm                         26                            61              37   15   25   0.873
  Distance from the anal verge                                                                
  ≥ 1 cm                         2                             4               2    2    1    
  \< 1 cm                        32                            72              48   19   33   0.853
  Histological grade                                                                          
  1                              1                             3               2    0    0    
  2                              28                            61              36   20   34   
  3                              5                             12              12   1    0    0.0732
  Histotype                                                                                   
  NOS                            28                            71              49   20   32   
  Mucinous                       6                             5               1    1    2    0.0875
  cT                                                                                          
  2                              2                             2               5         3    
  3                              23                            63              37   18   29   
  4                              9                             11              8    3    2    0.219
  cN                                                                                          
  cN0                            14                            28              21   10   25   
  cN+                            20                            48              29   11   9    0.008
  Death due to disease                                                                        
  No                             18                            56              34   18   31   
  Yes                            16                            20              16   3    3    0.0047
  Recurrence                                                                                  
  No                             15                            50              34   17   26   
  Yes                            19                            26              16   4    8    0.0254

![Distribution of Dworak regression score according to clinical Tumor Node Metastasis stage. Rectal cancers with cTNM stage II had a high proportion of Dworak grade 4 cases while tumors with cTNM stage III mainly had Dworak grade 1 regression.](WJG-23-1412-g002){#F2}

A total of 15 cases in our cohort were classified as mucinous on the endoscopic biopsy; 11 (73%) were classified as Dworak grade 0 or 1; 1 (7%) was classified as Dworak grade 2; 1 (7%) was classified as Dworak grade 3 and 2 (13%) were classified as Dworak grade 4 on the surgical specimen (Table [2](#T2){ref-type="table"}). A low Dworak grade (0-1-2) was more frequently observed in rectal carcinomas with mucinous histotype or high histological grade on the endoscopic biopsy, although statistical significance was not achieved (Table [2](#T2){ref-type="table"}). Among the patients with mucinous carcinoma, 5 (33%) died of disease, and 6 (40%) experienced disease recurrence (Table [1](#T1){ref-type="table"}).

Among the cases with Dworak grade 4, 7 (21%) had acellular mucin pools (Figure [1C](#F1){ref-type="fig"}); 5 (72%) originated from cTNM stage II cases; and 2 (28%) originated from cTNM stage III tumors. All of these cases were classified as yT0N0M0 stage and having an uneventful clinical course (no evidence of recurrence or death from rectal cancer in a median follow-up period of 71 mo; follow-up ranged between 71 and 183 mo). The presence of acellular mucin pools in Dworak 4 rectal cancer was significantly associated with mucinous histotype (*P* = 0.004) (Table [3](#T3){ref-type="table"}). Indeed, 2/34 cases had been classified as mucinous on endoscopic biopsy, and both had acellular mucin pools in the surgical specimen (Table [3](#T3){ref-type="table"}). However, the remaining five cases with acellular mucin pools showed no evidence of mucin in the endoscopic sample taken prior to CRT and surgery.

###### 

Statistical correlations between the presence of acellular mucin pools grade and clinico-pathological variables in Dworak 4 rectal carcinomas

  **Variable**                   **Acellular mucin pools**   ***P* value**   
  ------------------------------ --------------------------- --------------- --------
  Sex                                                                        
  M                              20                          6               
                                 7                           1               0.523
  Age                                                                        
  ≤ 67 yr                        13                          3               
  \> 67 yr                       14                          4               0.805
  Site                                                                       
  Upper                          14                          3               
  Medium                         4                           2               
  Lower                          9                           2               
  Extensive                      0                           0               0.695
  Circumferential spread                                                     
  One-third                      11                          3               
  Middle                         10                          2               
  Complete                       6                           2               0.898
  Craniocaudal extension                                                     
  \< 3 cm                        7                           2               
  ≥ 3 cm                         20                          5               0.889
  Distance from the anal verge                                               
  ≥ 1 cm                         1                           0               
  \< 1 cm                        26                          7               0.61
  Histotype                                                                  
  NOS                            27                          5               
  Mucinous                       0                           2               0.004
  cT                                                                         
  2                              2                           1               
  3                              23                          6               
  4                              2                           0               0.664
  cN                                                                         
  cN0                            20                          5               
  cN+                            7                           2               0.889
  Death due to disease                                                       
  No                             24                          7               
  Yes                            3                           0               0.362
  Recurrence                                                                 
  No                             19                          7               
  Yes                            8                           0               0.1047

In the comparison between cT and yT staging, we noticed that 86 (40%) cases showed no variation of T stage after CRT, 122 (57%) tumors underwent T downstaging, while 3% had T upstaging (Table [2](#T2){ref-type="table"}). T remaining unchanged/upstaging was significantly more frequent in female patients (*P =* 0.001) and in tumors with mucinous histotype (*P =* 0.01), cN+ stage (*P =* 0.014), high histological grade (*P \<* 0.0001) and low Dworak grade (0-1-2) (*P \<* 0.0001) and was significantly associated with death from rectal cancer (*P =* 0.002) and development of recurrence (*P =* 0.002) (Table [4](#T4){ref-type="table"}).

###### 

Statistical correlations between T stage variation and clinico-pathological variables

  **Variable**                   **T stage variation**   ***P* value**       
  ------------------------------ ----------------------- --------------- --- -----------
  Sex                                                                        
  M                              58                      83              0   
  F                              28                      39              7   0.001
  Age                                                                        
  ≤ 67 yr                        40                      64              2   
  \> 67 yr                       46                      58              5   0.375
  Site                                                                       
  Upper                          33                      56              4   
  Medium                         12                      19              1   
  Lower                          35                      41              1   
  Extensive                      6                       6               1   0.692
  Circumferential spread                                                     
  One-third                      41                      51              2   
  Middle                         22                      37              3   
  Complete                       23                      34              2   0.792
  Craniocaudal extension                                                     
  \< 3 cm                        21                      29              1   
  ≥ 3 cm                         65                      93              6   0.832
  Distance from the anal verge                                               
  ≥ 1 cm                         5                       6               0   
  \< 1 cm                        81                      116             7   0.789
  Histotype                                                                  
  NOS                            77                      118             5   
  Mucinous                       9                       4               2   0.01
  cN                                                                         
  cN0                            29                      66              3   
  cN+                            57                      56              4   0.0145
  Histological grade                                                         
  1                              0                       4               2   
  2                              68                      107             4   
  3                              18                      11              1   \< 0.0001
  Dworak grade                                                               
  0                              23                      7               0   
  1                              38                      35              7   
  2                              23                      27              0   
  3                              2                       19              0   
  4                              0                       34              0   \< 0.0001
  Death due to disease                                                       
  No                             52                      100             5   
  Yes                            34                      22              2   0.0027
  Recurrence                                                                 
  No                             45                      93              4   
  Yes                            41                      29              3   0.0014

Furthermore, 56 (48%) cases with cN+ status showed no change in N stage after CRT, while 61 (52%) had N downstaging. On the other hand, 13 cN0 (13%) rectal carcinomas underwent N upstaging after CRT (Table [3](#T3){ref-type="table"}). N remaining unchanged/upstaging was significantly more frequent in female patients (*P* = 0.0347) and in tumors with extensive involvement of the rectum or localization in the lower rectum (*P* = 0.0183), and low Dworak grade (0-1-2) (*P* = 0.0013) and was significantly associated with death from rectal cancer (*P* = 0.0043) and development of recurrence (*P* = 0.0013) (Table [5](#T5){ref-type="table"}).

###### 

Statistical correlations between N stage variation and clinico-pathological variables

  **Variable**                   **N stage variation**   ***P* value**        
  ------------------------------ ----------------------- --------------- ---- --------
  Sex                                                                         
  M                              19                      35              7    
  F                              37                      26              6    0.0347
  Age                                                                         
  ≤ 67 yr                        27                      34              5    
  \> 67 yr                       29                      27              7    0.565
  Site                                                                        
  Upper                          16                      33              7    
  Medium                         10                      11              3    
  Lower                          25                      16              1    
  Extensive                      5                       1               2    0.0183
  Circumferential spread                                                      
  One-third                      25                      28              8    
  Middle                         17                      17              1    
  Complete                       14                      16              4    0.582
  Craniocaudal extension                                                      
  \< 3 cm                        10                      14              5    
  ≥ 3 cm                         46                      47              8    0.27
  Distance from the anal verge                                                
  ≥ 1 cm                         1                       4               1    
  \< 1 cm                        55                      57              12   0.402
  Histotype                                                                   
  NOS                            49                      59              13   
  Mucinous                       7                       2               0    0.0851
  cT                                                                          
  2                              4                       8               0    
  3                              38                      42              12   
  4                              14                      11              1    0.265
  Histological grade                                                          
  1                              3                       2               0    
  2                              39                      50              11   
  3                              14                      9               2    0.512
  Dworak grade                                                                
  0                              14                      6               3    
  1                              25                      23              8    
  2                              16                      13              2    
  3                              0                       11              0    
  4                              1                       8               0    0.0013
  Death due to disease                                                        
  No                             30                      50              9    
  Yes                            26                      11              4    0.0043
  Recurrence                                                                  
  No                             25                      47              9    
  Yes                            31                      14              4    0.0013

On the whole, 80 (37%) cases showed no change in TNM stage, and 119 (55%) exhibited TNM downstaging, while 16 (8%) underwent TNM upstaging (Figure [3](#F3){ref-type="fig"}). In 13 cases, upstaging was due to development of nodal metastases, while, in 3 cases, upstaging was related to development of liver (2 cases) and peritoneal (1 case) metastases. Unchanged/increased TNM stage was significantly more frequent in cases showing extensive involvement of the rectum (*P* = 0.036), mucinous histotype (*P =* 0.04), cN+ stage (*P* = 0.001), and low Dworak grade (0-1-2) (*P \<* 0.0001) and was significantly associated with death from rectal cancer (*P* \< 0.0001) and development of recurrence (*P* = 0.001) (Table [6](#T6){ref-type="table"}).

![cTNM stage II rectal cancers mainly showed downstaging to yT0N0M0 or yTNM stage I. On the other hand, the majority of cTNM stage III cases had unchanged TNM stage after therapy, and some even showed upstaging to yTNM stage IV after therapy.](WJG-23-1412-g003){#F3}

###### 

Statistical correlations between Tumor Node Metastasis stage variation and clinico-pathological variables

                                 **pTNM stage variation**   ***P* value**        
  ------------------------------ -------------------------- --------------- ---- -----------
  Sex                                                                            
  M                              53                         81              7    
  F                              27                         41              6    0.655
  Age                                                                            
  ≤ 67 yr                        36                         65              5    
  \> 67 yr                       44                         57              8    0.372
  Site                                                                           
  Upper                          26                         60              7    
  Medium                         11                         18              3    
  Lower                          35                         41              1    
  Extensive                      8                          3               2    0.0194
  Circumferential spread                                                         
  One-third                      31                         55              8    
  Middle                         25                         36              1    
  Complete                       24                         31              4    0.396
  Craniocaudal extension                                                         
  \< 3 cm                        17                         29              5    
  ≥ 3 cm                         63                         93              8    0.4
  Distance from the anal verge                                                   
  ≥ 1 cm                         3                          7               1    
  \< 1 cm                        77                         115             12   0.747
  Histotype                                                                      
  NOS                            70                         117             13   
  Mucinous                       10                         5               0    0.043
  Histological grade                                                             
  1                              4                          2               0    
  2                              60                         108             11   
  3                              16                         12              2    0.135
  cT                                                                             
  2                              4                          8               0    
  3                              58                         100             12   
  4                              18                         14              1    0.185
  cN                                                                             
  cN0                            27                         58              13   
  cN+                            53                         64              0    \< 0.0001
  Dworak grade                                                                   
  0                              20                         11              3    
  1                              35                         33              8    
  2                              22                         26              3    
  3                              2                          19              0    
  4                              1                          33              0    \< 0.0001
  Death due to disease                                                           
  No                             47                         101             9    
  Yes                            33                         11              4    \< 0.0001
  Recurrence                                                                     
  No                             42                         91              9    
  Yes                            38                         31              4    0.0051

Univariate analyses showed that craniocaudal extension (*P* = 0.0225; *P* = 0.022) (Figure [4](#F4){ref-type="fig"}), cT (*P* = 0.0215; *P* = 0.021), yT (*P* \< 0.0001; *P* = 0.0001), yN (*P* \< 0.0001; *P* \< 0.0001) (Figure [5](#F5){ref-type="fig"}), yM (*P* = 0.0164; *P* = 0.005), ystage (*P* \< 0.0001; *P* = 0.0001), TNM stage variation (*P \<* 0.0001; *P* = 0.0005), T stage variation (*P \<* 0.0001; *P =* 0.001), Dworak regression grade (*P =* 0.0023; *P* = 0.023) (Figure [6](#F6){ref-type="fig"}), tumor regression (*P =* 0.0006; *P =* 0.01) (Figure [7](#F7){ref-type="fig"}) and radial margin (*P* = 0.0069; *P* = 0.025) were significant prognostic factors for CSS and DFS, respectively. Craniocaudal extension, yN status, radial margin status and tumor regression were independent variables in the multivariate analyses for CSS. On the other hand, craniocaudal extension (*P =* 0.0189), yT stage (*P =* 0.0327) and yN stage (*P =* 0.001) were significant prognostic parameters for DFS.

![Kaplan Meier curves showing cancer specific survival according to craniocaudal extension. Compared to tumors with craniocaudal extension lower than 3 cm rectal carcinomas with craniocaudal extension with higher cms had significantly shorter cancer specific survival (CSS).](WJG-23-1412-g004){#F4}

![Kaplan Meier curves showing cancer specific survival according to yN status. Compared to tumors with the presence of nodal metastases, rectal carcinomas with the absence of nodal metastases at histological examination of surgical specimen after chemo-radiotherapy (CRT) had significantly longer cancer specific survival (CSS).](WJG-23-1412-g005){#F5}

![Kaplan Meier curves showing cancer specific survival according to Dworak grade. Compared to tumors with Dworak grades 0, 1 or 2, rectal carcinomas with Dworak grades 3 and 4 had significantly longer cancer specific survival (CSS).](WJG-23-1412-g006){#F6}

![Kaplan Meier curves showing ancer specific survival according to tumor regression. Compared to tumors with absent/partial regression (Dworak 0, 1 and 2), rectal carcinomas with subtotal/total regression (Dworak 3 and 4) had significantly longer cancer specific survival (CSS).](WJG-23-1412-g007){#F7}

DISCUSSION
==========

In this study, we aimed to identify clinico-pathological variables, which may have significance for predicting recurrence risk and outcome in patients with rectal cancer submitted to neo-adjuvant CRT. Our findings can be summarized as follows. First, we confirmed previous evidence\[[@B7]-[@B9]\] that Dworak TRG is a reproducible histological parameter able to discriminate rectal carcinomas at the increased risk of recurrence or adverse outcome. However, the comparison of Kaplan-Meier curves showed that DFS and CSS were only slightly different between cases classified as Dworak 4 and 3 and among Dworak 0, 1 and 2 rectal carcinomas. These results suggested that a two-tiered rather than a five-tiered system could be used to grade tumor regression in surgical specimens. Accordingly, the use of a simplified dichotomized system, in which Dworak 0, 1 and 2 were considered as absent/partial regression and Dworak 3 and 4 as total/subtotal regression not only raised the inter-observer reproducibility but also increased the prognostic relevance of TRG; furthermore, two-tiered TRG was an independent and significant prognostic variable for CSS in the multivariate analysis. Moreover, the advantages of a simplified Dworak system were already demonstrated by Elezkurtaj et al\[[@B25]\] who showed that compared to Dworak's five tier system, dichotomized TRG has higher correlations with nodal disease and UICC stage. Finally, grouping Dworak grades 3 and 4 together would avoid the need to determine complete pathological response by using step sections, which is highly time consuming and whose benefits appear to be questionable\[[@B26]\]. Of note, a lower response to CRT (corresponding to Dworak TRG 0, 1 or 2) was observed in tumors showing mucinous histotype or poor differentiation in pre-treatment biopsy. Some authors recently suggested a "watch and wait" approach to avoid the side-effects of surgery in patients with rectal cancer showing complete clinical tumor regression after CRT\[[@B27]\]. Our findings indicate that caution should be used when applying a "watch and wait" policy to rectal cancer with mucinous or poorly differentiated histology, as these features are associated with a higher possibility of absent /incomplete tumor regression and T/TNM remaining unchanged/upstaging after CRT.

Seven (3.2%) rectal surgical specimens in our cohort showed acellular mucin pools upon histological examination. Two of those cases were derived from tumors with a mucinous histotype in the pre-treatment endoscopic biopsy. In those cases, acellular mucin deposits could be interpreted as a complete tumor response of mucinous rectal carcinoma. However, in 5 cases we could not find extracellular mucin in the pre-treatment sample, and this finding suggests that acellular mucin deposits in surgical specimens after CRT may represent a radiation effect, as was already hypothesized\[[@B28]\]. Of note, all 7 patients with acellular mucin pools had an unremarkable clinical course, with no recurrence or death from rectal cancer. This outcome supports the College of American Pathologists' consensus recommendation that acellular mucin pools should not be regarded as residual disease in rectal cancer treated with neo-adjuvant CRT\[[@B29]\]. Accordingly, we did not observe any significant difference in CSS and DFS between cases with acellular mucin pools and cases scored as Dworak 4. Hence, although acellular mucin pools are not mentioned in Dworak TRG\[[@B11]\], we may presume that due to the absence of neoplastic cells, they should be considered as complete tumor regression (Dworak 4). Our results are in line with those reported by other authors\[[@B15],[@B17]-[@B19]\]. However, some of the previous analyses could be flawed by the short follow-up of the patients, which was limited to 3 or 5 years\[[@B16]-[@B18],[@B30]\], or by sampling restricted to the macroscopically abnormal areas in the rectum\[[@B16]\]. In our cases with acellular mucin pools, the median follow-up time was 71 mo. Additionally, we overcame the possibility of the incorrect assessment of tumor response by embedding the entire surgical specimen and by cutting three additional leveled sections from each paraffin block in cases with questionable residual tumor. In our opinion, cutting step levels is mandatory when seeing acellular mucin pools after CRT. Indeed, this histological feature might represent either a treatment effect or residual tumor. Only careful histological examination of the entire surgical specimen with leveled sections allows for the exclusion of residual tumor. Moreover, a pre-treatment biopsy might not be representative of the entire tumor and may not show mucinous histology. Additionally, mucinous adenocarcinoma may show only rare foci of neoplastic cells that can be hard to identify.

Our results also showed that yN status is an independent predictor of shorter DFS and CSS in patients with rectal cancer submitted to neo-adjuvant CRT. Interestingly, 13% of patients with cN0 status had yN+ after therapy. This result highlights the importance of pathological examination after CRT to ensure appropriate staging and therapy of patients, as was already underscored\[[@B31]\]. Since N remaining unchanged/upstaging was significantly more frequent in tumors showing extensive involvement of the rectum or localization in the lower rectum, surgical resection and follow-up histological examination might have particular relevance in rectal carcinomas showing those features.

Tumor craniocaudal extension higher than 3 cm was an additional significant and independent prognostic parameter associated with worse DFS and CSS in our analyses. Since this feature was not associated with TNM variation or with tumor regression after therapy, we may speculate that cancers with higher craniocaudal extension might have had occult metastases undetectable at the moment of yTNM staging. However, our data suggest that particular attention should be given in the treatment and follow up of tumors existing at a higher extent in the rectum.

Finally, T and N remaining unchanged/upstaging was significantly more frequent in female patients. Although we are not able to explain this phenomenon, the role of hormones in the biological aggressiveness of rectal cancer should be better investigated in the future.

In conclusion, we confirmed the reproducibility and prognostic value of Dworak TRG in rectal cancer treated with neo-adjuvant CRT; however, our data suggested that a simplified two-tiered system may be used with better results. Acellular mucin pools in the surgical specimen may be considered as complete tumor regression, but step levels are warranted in those cases to exclude residual mucinous carcinoma. Finally, particular attention should be paid to rectal carcinomas showing the mucinous histotype, poor differentiation and extensive/lower involvement of the rectum due to the higher probability of absent/partial regression and TNM remaining unchanged/upstaging in those cases.

COMMENTS
========

Background
----------

Patients with locally advanced rectal cancer are currently submitted to neo-adjuvant chemo-radiotherapy (CRT) to improve resectability and sphincter preservation and to decrease the probability of local recurrence. Post-treatment Tumor Node Metastasis stage (yTNM) and Tumor Regression Grade (TRG) are used to measure tumor response in surgical specimens obtained after CRT. Several systems, such as the Dworak system, are used to score tumor regression. However, all these types of systems suffer from low interobserver reproducibility.

Research frontiers
------------------

A major issue in the interpretation of tumor histological response to CRT is related to the presence of acellular mucin pools. It is not clear whether these pools should be interpreted as complete regression. Finally, the value of clinico-pathological factors in predicting tumor regression after neo-adjuvant CRT remains to be determined.

Innovations and breakthroughs
-----------------------------

This article shows that, compared to the currently used four-tiered system a simplified two-tiered, Dworak TRG is preferable for determining score response to CRT because of its higher reproducibility and prognostic significance. Mucinous histotype and poor differentiation are significantly associated with lower response to neo-adjuvant CRT, as highlighted by higher frequency of absent/limited histological regression and TNM remaining unchanged/upstaging in those tumors.

Applications
------------

A simplified two-tiered, Dworak TRG could be used in routine practice to increase reproducibility and prognostic relevance of TRG. A watch and wait approach should be used with caution in rectal carcinomas showing mucinous histotype and poor differentiation in endoscopic pre-treatment biopsy due to their significant association with low response to pre-operative CRT.

Terminology
-----------

TRG: measure of the histological response to neo-adjuvant chemoradiotherapy, and it can be assessed by using different systems, such as that proposed by Dworak and colleagues in 1997, which is based on the presence of tumor cells and fibrosis in a surgical specimen. Acellular mucin pools: the presence of mucin deposits devoid of neoplastic cells in rectal surgical specimen after neo-adjuvant CRT that need to be differentiated from residual mucinous carcinoma.

Peer-review
-----------

A major finding reported in this study is the possible use of a two-tiered system to score TRG after neo-adjuvant chemoradiotherapy. Strength of this study is the high number (215 cases) of rectal carcinomas analyzed.
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